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ABSTRACT 
This thesis focuses on the analysis of RNA-Seq data in the context of cancer, 
ultimately leading to the identification of candidate genes to target for downstream 
analysis of their role in cell transformation and oncogenesis. Chapter 1 is a review of the 
current research being done with retinoblastoma deficient cancer, and the current 
bioinformatics solutions available for the analysis of high throughput sequence data, 
which will aid in molecular classification of tumor entities and in the identification of 
candidate genes to target for downstream analysis. Chapter 2 describes transcriptome 
analysis of a zebrafish RB1-primitive neuroectodermal tumor model as well as a 
zebrafish RB1 homozygous mutant. It begins with an introduction to the experimental 
design and background on both the tumor model and RB1 homozygous mutant. It then 
goes into the data analysis and biological interpretation of the results, from alignment of 
the raw reads to pathway analysis and identification of candidate genes that drive 
tumorigenesis. Chapter 3 of the thesis is attributed to a candidate gene discovered in the 
transcriptome analysis done in chapter 2, Chromodomain-helicase-DNA-binding protein 
7 (CHD7). It focuses on generating a somatic phenotype and ultimately the generation of 
germline mutants for genetic analysis into the role of CHD7 in normal brain 
development. Chapter 4 is independent of the previous two chapters, and describes the 
development of software to map Sleeping Beauty Transposon integration sites in the 
zebrafish genome.  It starts off with an introduction to the Sleeping Beauty Transposon, 
then focuses on the filtering of the raw read data generated from the sequencing of 
transposon junction fragments and the pipeline that maps the transposon insertion sites to 
viii 
                
 
 
the genome, ending with molecular verification of an insertion site via PCR and 
sequencing. The Appendix contains all supplementary information for Chapters 3-4. 
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CHAPTER 1: INTRODUCTION 
 
The first tumor suppressor gene cloned was retinoblastoma (RB1). For over four 
decades, there has been significant research into characterizing the functions of RB1, which 
has revealed it to be a key regulator in many biological pathways influencing cell fate, cell 
growth, cell-cycle checkpoints, differentiation, senescence, self-renewal, replication, 
genomic stability and apoptosis (Engel, et al. 2014). It is well known that RB1 suppresses the 
cell cycle by binding to E2F transcription factors and repressing expression of cell cycle 
target genes (Sun, et al. 2011). RB1 can also regulate gene expression by altering chromatin 
structure. A major example of this is RB1s ability to repress gene expression by recruiting 
chromatin modifying factors like histone deacetylases. In doing so, RB1 can establish the 
gene expression patterns necessary for controlling the cell cycle, cell fate, and differentiation 
(Chinnam, et al. 2011).  
With these diverse biological functions of RB1 in mind, it makes sense that it would 
have implications in many human cancers such as breast, lung, and parathyroid cancer (Jiang, 
e al. 2011; Sutherland, et al. 2011; Cetani, et al. 2003). Despite the great deal of knowledge 
in the literature about RB1s role in development and tumorigenesis, there is still not a good 
understanding of the detailed mechanisms that are triggered in these different biological 
processes. There is a critical need to fill this gap, so that researchers can identify important 
drug targets vital to the development of effective treatments for RB1 defective cancers.  
Cancer was first studied by taking a gene knockout approach, and using molecular 
genetics to deduce mechanisms (Wilson et al. 1973, Francke. 1976, Friend et al. 1986, Lukas 
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et al. 1995). Within the last two decades, high throughput nucleic acid sequence analysis has 
become increasingly popular, taking into account a whole genome picture as opposed to just 
a group of genes. Analysis such as RNA-Seq and ChIP-Seq can give a genome wide picture 
of gene expression and binding sites of the transcription factors and epigenetic regulators that 
control gene expression, respectfully. This has implications in cancer research as cancer 
genomes are very complex, with many genes differentially expressed. 
Recently, with the advent of next generation sequencing technologies and falling 
sequencing cost, taking the genomic approach is paving the way for understanding the 
mechanisms of many ailments and biological processes. In addition to making substantial 
advances in the field of genomics and bioinformatics, there has been remarkable advances in 
genome editing technologies. The CRISPR system has the ability to target a DNA Double 
Strand Break to essentially any gene of interest, making knockouts simple to make. In 
addition to this, one can take advantage of homology dependent DNA repair to attain precise 
genomic insertions, making conditional alleles and gene traps more obtainable.   
This review examines the current technologies available for genomic analysis, and 
how to interpret the data in a biological context using available software. Genome analysis 
reveals the state of the genome, that is which gene expression programs are in function in 
normal cells, and how these are altered in disease and throughout development. It also 
mentions some of the limitations to these technologies in regards to genome complexity and 
current available data. It critiques the current research being done in cancers involving RB1 
deficiency, and proposes where this interdisciplinary field of genetics and genomics needs to 
advance. 
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1.1: The RB1 tumor suppressor in brain cancer and neural development  
 
Primitive neuroectodermal tumors of the central nervous system (CNS-PNETs) are 
highly aggressive embryonal tumors. They mainly occur in younger children, though they 
can also occur in adults. These tumors are characterized by small, poorly differentiated cells 
with features similar to the embryonic neuroectoderm (Sturm et al. 2016). Currently, the only 
treatments available are invasive and harmful radio- chemo therapies and the overall 5-year 
survival rate for patients with CNS-PNETs is 50% (Larson et al. 2012). CNS-PNETs are 
often the result of mutation of the retinoblastoma tumor suppressor RB, or a deletion in 
CDKN2A, a negative regulator of cyclin-dependent kinases (CDK4/CDK6) that inhibit RB1 
(Pfister et al. 2007). RB1 is a negative regulator of E2F transcription factors that function in 
cell cycle control (Chen et al. 2009). Mutations in RB1 result in retinoblastoma, an eye 
cancer, however, those with retinoblastoma can also develop CNS-PNETs (de Jong et al. 
2015). Inactivation of RB1 is also seen in other types of cancer such as lung and prostate 
cancer (Meuwissen et al. 2003, Phillips et al. 1994). Our group has shown that somatic 
inactivation of RB1 in zebrafish via transcription activator-like effector nucleases (TALENs) 
or CRISPR/Cas9 results in highly proliferative tumors that resemble human PNET in 
pathology (Solin et al. 2015) and molecular signature (Schultz et al. in press). 
Transcriptomics of our zebrafish RB1-tumors show that these tumors harbor a 
progenitor-like molecular signature, with altered expression of genes involved in the self-
renewal of neural stem/progenitor cells. The zebrafish RB1-tumors are highly proliferative 
and have reduced expression of neuronal and glial markers showing that they are poorly 
differentiated. This evidence indicates the importance of RB1 in normal brain development 
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as well as in tumorigenesis. In addition to this, differential gene expression analysis of the 
zebrafish RB1-tumor transcriptome also revealed altered expression of many chromatin 
remodelers.  
Epigenetics is responsible for the regulation of many genes, so it is no surprise that it 
plays an important role in cancer. Epigenetics is any alteration to gene expression without 
altering the genetic code itself. These epigenetic modifications are carried out by a wide 
array of complexes that can repress or activate a gene by making modifications to the 
histones in which the chromatin is made of (Clapier et al. 2009). Histone deacetylates and 
methyltransferases usually repress gene expression, though they can activate it as well, while 
Histone acyltransferases and histone demethylases usually activate gene expression, though 
they can repress it as well. In addition to this complexes such as DNA helicases that 
restructure nucleosomes can also regulate gene expression (Brennan et al. 2016). All these 
histone modifiers and chromatin remodelers alter gene expression my physically modifying 
the chromatin structure, which is what chromosomes are made of (protein, RNA, and DNA). 
Indeed, global changes in the epigenetic landscape are a major hallmark of cancer 
(Sharma et al. 2010). There is extensive research on the disrupted signaling that occurs in 
cancer, which has generated much needed knowledge, however, less is known about 
regulation of the epigenetic landscape and how it connects with the transcriptome during 
tumorigenesis (Malysheva et al. 2016). 
 One such chromatin remodeler that interacts with RB1 is RB1 Binding Protein 4 
(Rbbp4). Rbbp4 was first discovered with its binding partner tumor suppressor 
Retinoblastoma (RB1) in yeast (Qian et al. 1993). Rbbp4 is a chromatin adapting protein that 
is overexpressed in our RB1- tumor transcriptome. Rbbp4 has also been found to be 
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upregulated in zebrafish liver and human breast cancer (Lam et al. 2006, Nagai et al. 2003). 
Rbbp4 is a component of the DREAM complex which represses gene expression during cell 
cycle quiescence. Miss regulation of DREAM can shift the balance in the cell cycle from 
quiescence to proliferation and can contribute to increased mitotic gene expression levels 
regularly observed in cancers (Sadasivam et al. 2013).  Rbbp4, is a component of several 
important chromatin remodeling complexes, and it is thought that main role of Rbbp4 is to 
bind to chromatin and recruit the components of the chromatin remodeling complex as well 
as to provide specificity and stability to the complex. Rbbp4 is highly conserved in 
organisms, ranging from plants, to invertebrates, to mammals (Ach et al. 1997) (Guitton et al. 
2005) (Souza et al. 2002) (Wen et al. 2012). The structure of Rbbp4 is a WD40 domain 
protein exhibiting a 7-blade β-propeller structure (Migliori et al. 2012). Rbbp4 binds to 
histone H3 through a binding pocket on the top of the β-propeller and it binds to H4 through 
a binding pocket on the side of the β-propeller (Song et al. 2008; Torrado et al. 2017) 
(Nowak et al. 2011) (Zhang et al. 2013) (Lejon et al. 2011). Rbbp4 and RB1 are components 
of the repressive deacetylase containing NuRD complex (Xue et al. 1998) (Zhang et al. 
1999), which is involved DNA damage repair, stem cell biology, and development (Basta et 
al. 2015) (Denslow et al. 2007) (O’Shaughnessy et al. 2013). Rbbp4 is also a member of 
repressive complexes SIN3 (Vermaak et al. 1999) and PRC2 (Kuzmichev et al. 2002) (Vaute 
et al. 2002) (Margueron et al. 2008) which repress gene expression via deacetylation and 
methylation of histones, respectively. In addition to its role in repressive complexes, Rbbp4 
is also involved in CBP/p300 (Zhang et al. 2000) a histone acetyl transferase that activates 
gene expression. With these multiple functions of RBBP4 in mind, it seems likely that RB1 
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and RBBP4 work together in many processes that could have implications in tumorigenesis 
such as cell cycle control, DNA damage repair, and stem cell maintenance.  
As mentioned previously, RB1 has been proven to be a key regulator in many 
biological pathways that control cell division and development. In doing so, RB1 can 
establish the gene expression patterns necessary for controlling the cell cycle, cell fate, and 
differentiation (Chinnam, et al. 2011). It may be known that Rbbp4 and RB1 can modify the 
epigenetic landscape, however, the details of these mechanisms are not well understood.  
In a study by (Malysheva et al. 2016) they used an isogenic model of stepwise 
tumorigenic transformation of human primary cells to monitor the mis-expression in gene 
networks upon immortalization and oncogene-induced transformation. Using a systems 
biology approach, they combined transcriptome and epigenome data for each step during 
oncogenic transformation and integrated transcription factor–target gene associations so that 
they could reconstruct the gene regulatory networks that are the cause of the transformation 
process. In doing so, they identified 142 transcription factors and 24 chromatin remodelers 
associated with tumorigenesis. Studies like this open up the possibility for the direct 
implication of chromatin remodelers in oncogene-induced tumorigenesis.  
There is a great deal of importance in uncovering the epigenetic mysteries of cancer, 
however, there is also a growing need to classify cancers based on their molecular signatures 
in order to understand the underlining gene expression patters that govern them. In a study by 
(Picard et al. 2012) they used unsupervised hierarchical and non-negative matrix 
factorization clustering on a list of genes to identify three distinct molecular subgroups of 
human-CNS PNETs. It was discovered that the gene LIN28 was expressed at high levels and 
OLIG2 was expressed at low levels in group 1 PNET tumors, whereas in group 2 tumors 
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there was high OLIG2 and little LIN28 expression. In group 3, LIN28 and OLIG2 expression 
was low or absent. When performing a supervised analyses, it was revealed that the three 
subgroups showed signiﬁcant diﬀerences in neural lineage and diﬀerentiation genes. Group 1 
were most signiﬁcantly enriched for genes associated with embryonic or neural stem cells. 
Group 2 tumors were enriched for genes associated with neural progenitors and group 3 
tumors showed reduced expression of genes involved in neural diﬀerentiation but displayed 
an upregulation of epithelial and mesenchymal differentiation genes. This study highlights 
the importance of defining subgroups when inferring the mechanisms that cause cancer.  
Indeed, understanding both chromatin modification and the mis-expression of 
developmental genes is important in cancer research, as it may provide insight into the 
mechanisms that allows unregulated growth of cancer cells. Epigenetics can regulate gene 
expression beyond the level of the basal transcription machinery while the mis-expression of 
different developmental genes can lead to different types of cancer. Identifying how the 
altered expression of genes drives cancer may yield new information on methods to block 
tumor cell proliferation and survival. 
 
1.2: Next-Generation Sequencing technologies and available analytical software. 
 
High-throughput DNA sequence analysis represents a single format which can 
address many questions in biology. In the past decade, massively parallel DNA sequencing 
platforms have become abundant, causing the cost of DNA sequencing to drop by over two 
orders of magnitude, making large scale sequencing affordable to individual investigators. 
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With these new technologies rapidly evolving, experiments such as RNA-Seq, ChIP-Seq, 
whole genome sequencing, and a variety of others are becoming increasingly popular in 
many fields of biology.   This technological revolution in sequencing calls for the 
development of robust protocols for generating sequencing libraries, developing new 
statistical methods for data-analysis, and even a rethinking of experimental design to reduce 
unwanted variability in the data generated (Shendure et al. 2008). 
 
Methods of Mapping Raw-Reads to Genomes 
There are many available read aligners out there, many of which are open source. 
Some of these more popular ones include Stampy, TopHat, and GSNAP. Each aligner has a 
unique algorithm that has advantages and disadvantages in certain situations.  
A comparison of these three different aligners has been done in a study by (Nookaew 
et al. 2012). Stampy was found to be the most time costly of the three aligners, however, it 
showed the highest mapping accuracy for open reading frames (ORFs) with high genetic 
variation. This would be useful when working with genomes and transcriptomes of higher 
eukaryote organisms, because they usually contain high variation in exons ((Gamazon et al. 
2010, Frazer et al. 2007), as cited in Nookaew et al. 2012). The high accuracy of Stampy is 
because it implements a seed-based method, which is superior at mapping reads on a 
polymorphic region. A downside of this aligner is that it is a non-splicing aligner, so spliced 
junctions/events are not detected. GSNAP was found to be the fastest of the three aligners, 
and it is a spliced aligner enabling splice junctions to be detected. This would be particularly 
useful in RNA-Seq experiments. A downside of GSNAP is that it does have a lower mapping 
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accuracy compared with the other aligners when mapping to highly polymorphic regions, 
meaning it would work best for the analysis of massive amount of data over a genome that 
contains low polymorphisms. The TopHat aligner was found to be a compromise between 
speed and accuracy and it also performed well at aligning reads to small exons. Like 
GSNAP, TopHat is a spliced aligner, also making it useful for RNA-Seq experiments, 
however, it must be used with a non-spliced aligner such as Bowtie because TopHat only 
performs the splice junction detection step.  
When performing an RNA-Seq experiment, speed as well as accuracy must be taken 
into account with a tradeoffs between speed and accuracy. GSNAP being a very fast and 
simple to use aligner, as well as being a spliced aligner makes it a popular choice for RNA-
Seq analysis. Recently, GSNAP has progressed along with advances in biological 
methodology so that it can handle longer reads, larger amounts of data, and new types of 
biological assays (Wu et al. 2016). 
Another important consideration when mapping reads is whether or not there is a 
reference genome. There are many well annotated reference genomes such as mouse, human 
and zebrafish, which are all publicly available. If one does not have a reference genome to 
work with, assembling a genome de novo can be costly as well as computationally intensive. 
Despite this, if one wishes to go this route, a high consistency between the de novo and 
reference genome approach has been found, in terms of number of detected transcripts, 
expression values and differentially expressed genes (DEGs) identified (Nookaew et al. 
2012). 
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Differential Gene Expression Analysis 
Differential gene expression (DGE) analysis is an essential step in the RNA-Seq 
analysis pipeline. It identifies genes that are predicted to contribute to a phenotype or disease, 
and that are worth investigating experimentally, given a statistical cut-off. There are many 
different available statistical methods for the identification of differentially expressed genes 
(DEG). In a study by (Nookaew et al. 2012), they assessed the impact of different statistical 
methods on the identification of DEGs. They found that the popular statistical methods 
Cuffdiff, baySeq, DESeq, edgeR and NOISeq generated consistent results coming to similar 
biological interpretations using GO enrichment analysis. Interestingly they found high 
consistency between microarray and RNA-Seq platforms for identifying DEGs, thus 
encouraging the continued use of microarray platforms for DGE analysis.  
In recent years, edgeR and DESeq have been included in several important studies 
((Soneson. 2013, Rapaport 2013) as cited in Varet et al. 2016) and perform well in replicated 
experiments. Since then, the successor to DESeq, DESeq2 (Love et al. 2014) as well as 
edgeR (Robinson et al. 2009) have become very popular Bioconductor (Gentleman. 2004) 
packages for DGE analysis. They are both very well documented and easy-to-use, even for 
those who are not familiar with the R language. The normalization methods associated with 
edgeR and DESeq2 have been shown to be superior to other statistical methods, in particular 
when the expressed RNA in each sample varies across biological conditions or when there 
are genes that highly expressed present (Dillies et al. 2012, as cited in Varet et al. 2016). 
Although both methods are popular and effective at detecting DEG, the results are not 
exchangeable. This is because DESeq2 uses computed size factors in the estimation of the 
mean of the Negative Binomial distribution, while edgeR uses scaling factors which apply to 
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library sizes (total counts), the normalized library sizes being included as an offset parameter 
in the statistical model (Varet et al. 2016). Interestingly, in the study done by (Nookaew et al. 
2012), edgeR detected more DEGs than the other methods at the same statistical cut-off, 
which could be from less control of type 1 errors. 
Biological Interpretation of Results 
The interpretation of high-throughput gene-expression data is the last and arguably 
the most important step in a gene expression study. It requires a fundamental understanding 
of what biological question is being asked and possibly what to expect. There are many 
software programs available that perform this step of the analysis, making interpretation of 
gene expression data simple and intuitive to researchers. This can be done using gene-set-
enrichment methods that implement statistics to analyze differentially expressed genes and 
link them to particular biological functions or pathways.  
One such method is Gene Set Enrichment analysis (GSEA), which is a free software. 
GSEA implements statistical techniques to identify categorical biases within a list of genes, 
metabolites, or proteins, with the goal to discover shared functions or properties of the 
biological items in the list (Tilford et al. 2009). This ultimately provides biological insight 
from the gene expression data, including discovery of interacting genes or regulators, 
participation in the same biological function, common cellular compartmentalization, or 
association with specific diseases (Tilford et al. 2009). 
Ingenuity Pathway Analysis (IPA) is another commercially available method that 
while still depending on statistics, is more powerful than Gene-Set Enrichment Analysis 
since it uses knowledge about the direction of effects rather than just associations. Also, the 
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data input into IPA has already been determined to have differential expression. This is 
different from GSEA, where in general there is no guarantee that the genes in the pathway 
are differentially expressed upon pathway activation or inhibition. The IPA algorithm takes 
advantage of current knowledge from the individual literature-supported relationships 
between diseases, molecules and biological processes that is in the Ingenuity Knowledge 
Database (Krämer et al. 2013). 
1.3: Discussion. 
Epigenetics is the hallmark of many types of cancer, and understanding how 
chromatin structure affects gene expression will be key to uncovering many secrets on what 
underlines cancer. Primitive neuroectodermal tumors of the central nervous system are a 
highly malignant type of cancer that can result from RB1 deficiency. Using RNA-Seq, our 
group has shown that there are many chromatin remodelers differentially expressed in our 
zebrafish PNET model. Unraveling the epigenetic mechanisms that underline PNETs will be 
a necessary step in moving forward with finding potential drug targets.  
The use and analysis of genomic data is essential to answering many questions in 
biology.  It can allow researchers to step back and look at the whole picture of what’s going 
on at the whole genome level, which can lead to new insights in the experimental system in 
question. Using this technology it is possible to gain insight into the state of the whole 
genome, which can allow for the identification of candidate genes worth targeting to further 
deduce the mechanisms underlining a phenotype or disease.   
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CHAPTER 2: TRANSCRIPTOME ANALYSIS OF ZEBRAFISH RB1-DEFECTIVE 
BRAIN TUMORS  
2.1: Introduction. 
 
Recent comparative genomics of human and mouse retinoblastoma tumors highlights 
the importance of epigenetic regulation in tumorigenesis (Aldiri et al. 2017; Benavente et al. 
2013; Zhang et al. 2012). The retinoblastoma tumor suppressor, RB1, is a negative regulator 
of E2F transcription factors that function in regulating the cell cycle (Chen et al. 2009) and 
also has roles cell fate, cell growth, differentiation, senescence, self-renewal, replication, 
genomic stability and apoptosis (Engel, et al. 2014). Mutations in RB1 result in 
retinoblastoma, an eye cancer, however, those with retinoblastoma can also develop CNS-
PNETs (de Jong et al. 2015). Understanding the epigenetic modifications that result from 
loss of RB1 in neural stem and progenitor cells and in brain cancer is important for 
discovering potential drug targets for tumor inhibition.  
We previously demonstrated that somatic targeting of RB1 with genome editing 
nucleases in zebrafish results in brain tumorigenesis (Solin et al. 2015). Targeting RB1 in 
zebrafish with TALENs results in brain tumors that are histologically similar to primitive 
neuroectodermal tumors (PNET) (Solin et al. 2015). PNETs are a group of highly malignant, 
poorly differentiated tumors that feature neuroblast-like cells, suggesting that this class of 
tumors originate from a neuro progenitor population (Chan et al. 2015, as cited in Ostrom et 
al. 2017).  
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Recently, there have been other zebrafish PNET models developed by somatic 
targeting or oncogene overexpression. Targeting RB1 in a TP53-mutant background 
produces medulloblastoma-like PNET tumors (Shim et al. 2017). Overexpression of 
RAS/MAPK signaling in oligoneural precursors leads to formation of PNETs (Modzelewska 
et al. 2016) that have a similar molecular signature to human oligoneural PNET subtype 
Olig2+/Sox10+ CNS-PNET (Picard et al. 2012; Sturm et al. 2016), defined by over 
expression of the neural progenitor transcription factors OLIG2, SOX10, SOX8 and SOX2. 
Together, these models suggest that disruption of multiple pathways can result in PNET 
formation. From the genomic analyses of human and mouse tumors, it is suggested that 
epigenetics is associates with tumorigenesis. Whether epigenetics contributes to zebrafish 
PNET oncogenesis, has yet to be examined. 
In this chapter, I present a transcriptomic analysis of our zebrafish PNET model that 
results from somatic targeting of RB1 with TALENs or CRISPRs (Solin et al. 2015, Schultz 
et al. 2018). Transcriptome analysis was also performed on zebrafish mutant larva that were 
homozygous for a recessive lethal loss of function frameshift allele RB7/7 (Schultz et al. 
2018). A comparative analysis between the tumor and mutant transcriptomes was performed 
to identify molecular pathways that distinguish transformed RB1- tumor cells from non-
transformed RB/7 mutant cells.  
The RNA-Seq analyses were performed with the most up to date zebrafish 
reference genome, V10, and implement some popular software packages, the majority of 
which are open source. The sensitivity of an RNA-Seq experiment will be a function of 
both molar concentration and transcript length. Therefore I quantified transcript levels in 
reads per kilobase of exon per million mapped reads (RPKM) (Mortazavi et al. 2008). The 
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RPKM measure of read density mirrors the molar concentration of a transcript in a sample 
by normalizing for gene exonic length and for the total read number in the measurement 
(Mortazavi et al. 2008). This type of read normalization will allow for the comparison of 
transcript levels both within and between samples. This study provides new insight into the 
genomic processes that drive tumorigenesis in RB1-defective brain tumors. Comparative 
transcriptome analysis of zebrafish RB1-defective adult brain tumors with RB/7 mutant 
tissue identified unique neural progenitor transcription factors and chromatin remodelers that 
distinguishes transformed from mutant tissues. 
 
2.2: Methods 
 
Zebrafish RB1-tumor and RB/RB1 mutant RNA-Seq library preparation 
RNA-Seq libraries were prepared from 10 tumor biological replicates and two pools 
of 3 normal adult brains, each with a technical replicate.  A 7-base pair frameshift mutation 
in RB1 exon 2, RB1/7 is homozygous lethal during the larval stage between five and ten 
days post- fertilization (dpf) (Solin et al. 2015). To generate the RB1/7 transcriptome, 5 
dpf larva were collected from an in cross between two heterozygous RB1/+ adults. Six 
confirmed wildtype Rb1 +/+ and homozygous RB1/7 heads were pooled in triplicate and 
used to prepare RNA-Seq libraries. 
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Read alignment, and quantification of gene expression. 
Reads were aligned to the GRCz10 zebrafish reference genome using GSNAP 
version 20150723 with the following parameters “-N 1 -t 8 -B 4 -m 5 -A sam --split-output”. 
This allows for splicing during the alignment, a maximum of 5 mismatches, and the creation 
of separate SAM output files for each output type. Using HT-Seq 0.9.1 a count table was 
generated using the GSNAP “uniq” SAM files along with the Danio_rerio.GRCz10.89.gtf 
file for annotation. To quantify gene expression, Fragments Per Kilobase of transcript per 
Million mapped reads (RPKM) was calculated using the following equation RPKM= (10^9 x 
Number of mapped reads to a gene)/ (Gene exonic length x Total mapped reads in the 
experiment). The count table was used to gather read number and the gene exonic length was 
calculated from the Danio_rerio.GRCz10.89.gtf file in R using the “GenomicFeatures” 
package from Bioconductor. 
 
Differential gene expression analysis  
Count data generated from HT-Seq was used for differential gene expression analysis 
using DESeq2. The counts were summed across technical replicates. For a gene to be 
considered differentially expressed, it must have an adjusted p-value of less than or equal to 
0.01 and at least a 1.5 fold change in either direction.  
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Gene Set Enrichment analysis 
Gene Set Enrichment analysis (GSEA) was done with the Broad Institutes GSEA 
software using the RPKM values for every gene in the genome for all samples as input. The 
RPKM values were averaged across technical replicates for GSEA.  
 
Generation of Heatmaps: 
Heatmaps were generated from Log2(RPKM+1) values, RPKMs averages across 
technical replicates, using ether heapmaps.2 from the “gplots” package in R or using the 
Broad Institutes GENE-E. The correlation coefficient plots were computed in Microsoft 
Excel using the CORREL function which computes the correlation coefficient between two 
arrays of RPKM values for every gene in the genome using two samples at a time.  
 
Principal Component Analysis 
 Principal component analysis was performed using the prcomp function in R. The 
data input was normalized gene expression values (RPKM) for every gene in the genome and 
for all samples in both RNA-Seq experiments.  
 
Ingenuity Pathway Analysis 
 Ingenuity pathway analysis (IPA) was performed using the IPA software from 
QIAGEN. The input for IPA was the list of genes identified in the differential gene 
expression analysis. The cut off for a gene being considered differentially expressed is that it 
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must have p-value of less than or equal to 0.01 and at least a 1.5 fold change in either 
direction.  
 
2.3: Results. 
 
GSNAP read alignment  
On average there were about ~15 million reads in each RB1-tumor transcriptome 
library (Table 2.1) and about ~30 million in each RB/7 transcriptome library (Table 2.2).  
The majority of the reads mapped uniquely to the zebrafish v10 reference genome (>90%), 
with the rest mapping to multiple places in the genome and some being unmapped.  
 
 
 
 
 
 
 
 
 
Table 2.2 
Table 2.1 
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Normalization of raw read counts: 
Reads were normalized using the RPKM approach. This allowed for within and 
between sample comparisons taking as this method takes into account the molar 
concentration and gene length. The technical replicates correlate nicely with their 
corresponding replicate for both RNA-Seq experiments as seen by the positive linear 
relationship (Figure 2.1 A, B). Correlation coefficient plots reveal homogenous relationship 
between the tumor samples as well as between the control samples, all with a R2 near one, 
and a poor correlation between tumor and control with an R2 under 0.8 ( Figure 2.1C). 
RB/7 mutant samples and control samples correlate well with each other and in their 
respective groups all with a R2 above 0.95, which is to be expected from mutating only one 
gene (Figure 2.1D).  
A.)  
 
 
 
 
 
 
 
Figure 2.1 Comparison of samples in RB1-tumor and RB7/ 7 transcriptomes A.) RB1-
Tumor RNA-Seq RPKM values for each sample plotted between technical replicates. 
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B.)                                                                                        D.) 
 
 
 
 
 
Figure 2.1 (Continued) B.) RB/7 mutant RNA-Seq RPKM values for each sample 
plotted between technical replicates. C.) R2 values from comparing RPKM values in all 
samples to each other and to themselves for the zebrafish RB1-tumor transcriptome (T = 
tumor sample, C = control sample. D.) R2 values from comparing RPKM values in all 
samples to each other and to themselves for the RB/7 mutant transcriptome (Mut = 
mutant sample, Wt = Wildtype sample). 
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Principal component analysis shows separation of Control and Tumor: 
Normalized expression values, RPKM, were plotted using the prcomp function in R 
using all samples. The first two variance components contained the majority of the variation 
the data (Figure 2.2B). The plots clearly show a separation of tumor and control 
transcriptomes (Figure 2.2A). The fact that all Control treatments are grouped in the bottom 
right in grey while all the Tumor treatments are grouped in the top left in blue is encouraging 
because the variation in the diﬀerent Tumor treatments is not so large to get confused with 
the Control treatments. There is also a clear separation of RB/7 and wildtype though not 
as prominent (Figure 2.2A), though this is to be expected since only one gene is mutated in 
the RNA-Seq.  
A.)                                                                                         B.) 
 
 
 
 
 
 
Figure 2.2 Principal component analysis of RB1-tumor and RB17/7 transcriptomes. 
A.) Principal component plot of both transcriptomes, RB1-tumor and RB1/7. C = control 
for tumor transcriptome, T = RB1-tumors, WT = wildtype control for RB1/7 
transcriptome, Hom = RB1/7  mutants. B.) Variance in first 10 principal components.  
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Differential gene expression Analysis 
Using the bioconductor package DESeq2, 11103 differentially expressed (DE) genes 
were identified in the RB1 Tumor transcriptome, with 5684 being down regulated and 5419 
upregulated (Figure 2.3A). In the RB/7 mutant transcriptome, 1024 DE genes were 
identified with 421 being down regulated and 603 up regulated (Figure 2.3B). For a gene to 
be considered as DE, it must have at least a 1.5 fold change in either direction and have a P 
value =< 0.01.  
A.) RB1-Tumor 
 
 
 
   
B.)  RB/7   
 
 
 
 
Figure 2.3 Plots of differentially expressed genes in RB1-tumor and RB17/7 
transcriptomes. A.) Plot of log2FoldChange for tumor compared with Control vs P-Value, 
each dot represents a differentially expressed gene. B.)  Plot of log2FoldChange for 
RB17/7 compared with Wildtype vs P-Value, each dot represents a differentially expressed 
gene.  
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Comparison of zebrafish RB1 tumor and RB/7 mutant transcriptomes supports 
epigenetics drive RB1-defective tumorigenesis and tumor growth. 
 
It is well known that altered chromatin plays a key role in tumorigenesis as well as in 
development. Of the 3302 Transcriptional Regulators in the zebrafish genome (Armant et al. 
2013), 122 (3.7%) are DE in the RB/7 Mutant and 1191 (36.1%) are DE in the RB1-
Tumor. Interestingly, in the tumor transcriptome, about half are down regulated and half are 
up regulated (Figure 2.4A). The majority of the transcriptional regulators DE in both 
transcriptomes are transcription factors, with a fifth of the total being chromatin remodelers 
in the RB1-tumor (Figure 2.4B).   
However, there are some key difference between the two transcriptomes. In only the 
RB1-tumor transcriptome, there is up-regulation of stem and neural progenitor transcription 
factors sox2, sox8, sox10, olig2, and ascl1b, and downregulation of proneurogenic 
transcription factors pax6a, pax2a, neurod1, and neurod6a (Figure 2.4C). This is indicative of 
the tumors consisting of populations of neural stem/progenitor cells that are not 
differentiating into neurons and glial cells.  
The chromatin adaptor rbbp4, a component of multiple chromatin remodelers 
controlling gene expression including NuRD, PRC2, histone acetyltransferase p300 and the 
cell cycle DREAM/MuvB complex, was upregulated in both rb1 tumor (7.8-fold, 
Padj<0.00001) and rb1/rb1 mutant (2.3-fold, Padj<0.00001) transcriptomes. Like rbbp4, 
hdac1, the catalytic component of NuRD, and mbd3a, a DNA binding subunit, were both 
significantly overexpressed in the rb1 tumor (hdac1 3.6-fold, Padj<0.00001; mbd3a 6.1-fold, 
Padj<0.00001). Although hdac1 and mbbd3a were also upregulated in the rb1/rb1 mutant 
(hdac1 1.3-fold, Padj=0.00123; mbd3a 1.2-fold, Padj=0.06262), neither was as highly 
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elevated as rbbp4. qRT-PCR confirmed the change in gene expression for rbbp4 and hdac1 in 
rb1 tumor tissue (Figure 2.4D) and in the 5 dpf rb1/rb1 mutant larvae (Figure 2.4D). The 
differences in gene expression between tumor and mutant suggest that expression of neural 
stem and progenitor transcription factors, along with with altered chromatin remodeler 
activity, correlates with transformation of rb1 mutant cells, maintenance of the tumor 
progenitor-like state and tumor oncogenesis. 
 
A.)                                                                                  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4 Transcriptomes reveal altered expression of Transcriptional regulators.      
A.) Heatmap of transcriptional regulators DE in RB1-tumor transcriptome. 
 
 
 Log2(RPKM) 
29 
                
 
 
 
B.)  
 
 
 
 
 
 
 
 
C.)  
 
 
 
 
 
D.)  
 
 
 
Figure 2.4 (Continued) B.) Heatmap of transcription factors and chromatin remodelers of 
interest for each transcriptome, RB1-tumor and RB1/7. C.) Venn diagram of transcription 
factors and chromatin remodelers DE in each and in both transcriptomes. D.) QRT-PCR 
validation of RNA-Seq findings in C. 
Log2(RPKM) 
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Zebrafish RB1-defective brain tumors model Human Olig2+/Sox10+ CNS-Primitive 
Neuroectodermal Tumors. 
Human PNET tumors have been classified into subgroups based on differential gene 
expression and other statistical methods (Modzelewska et al. 2016, Picard et al. 2012). 
Transcriptomic analysis of the Zebrafish RB1-defective tumors has revealed that they harbor 
a neural progenitor gene signature as well as elevated gene expression of Olig2 and Sox10 
(Figure 2.4C), both indicative of the Olig2+/Sox10 subtype of PNET.  
These Zebrafish RB1-tumors have an upregulation of E2F target genes which drive 
cell cycle entry (Figure 2.5B). This is to be expected in the absence of RB1 since it normally 
inhibits E2F transcription factors. Complementing this finding, Ingenuity Pathway Analysis 
(IPA) revealed activation of pathways involved in mitosis, cell cycle, and DNA replication, 
recombination and repair (Figure 2.5C).  
Gene Set Enrichment Analysis (GSEA) analysis indicated a positive enrichment of 
genes indicative of embryotic stem cells and pediatric markers, with a negative enrichment of 
neurological processes (Figure 2.5A). This supports the idea that the Zebrafish RB1-tumor 
model has a neural progenitor signature with poor differentiation status.  In addition to this 
GSEA revealed a positive enrichment of RB1-E2F oncogenic cell signaling and 
transcriptional regulation pathways (Figure 5A). These results RB1-dependent pathways 
driving oncogenesis in the RB1-defective brain tumors. 
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A.) 
 
 
 
 
 
 
 
 
 
 
 
 
B.)   
 
 
 
 
 
 
 
 
 
Figure 2.5 Zebrafish RB1 tumors have a neural progenitor signature with an 
upregulation of E2F cell cycle target genes. A.) Gene set enrichment analysis of Zebrafish 
RB1-tumor transcriptome, Tumor vs Control B.) Heatmap of RPKM expression values for 
E2F cell cycle target genes in Zebrafish RB1-tumor transcriptome.   
Log2(RPKM) 
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C.) 
 
 
 
 
 
 
 
Figure 2.5 (Continued) C.) Ingenuity Pathway Analysis of differentially expressed genes in 
Zebrafish RB1-tumor transcriptome.  
 
 
The RB1-tumor transcriptome was then compared to another zebrafish PNET brain 
tumor model and to human central nervous system (CNS) primitive neuroectodermal tumors 
(PNET). A gene set consisting of 120 genes, which are the 60 most highly upregulated and 
the 60 most downregulated genes in the human Olig2+/Sox10+ CNS-PNET subtype (Picard 
et al. 2012) was recently used to analyze differential gene expression in a zebrafish NRAS-
CNS- PNET model (Modzelewska et al. 2016). This analysis showed that the zebrafish 
NRAS-CNS-PNET had a similar expression to the Human Olig2+/Sox10+ CNS-PNET 
subtype. The zebrafish RB1-tumors showed a similar pattern of gene expression across the 
60 up- and 60 downregulated genes (Figure 2.6A). Genes symbolic to the Human 
Olig2+/Sox10+ CNS-PNET subtype, olig2, sox10, sox8 and erbb3a, and the stem/progenitor 
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marker sox2 were overexpressed in the zebrafish RB1- tumors (Figure 2.6B). These results 
taken together demonstrate that the zebrafish RB1-tumors share strong similarities to the 
human Olig2+/Sox10+-CNS- PNET subtype, as they both have a highly proliferative, poorly 
differentiated state with an oligoneural precursor molecular signature. 
A.) 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6 Zebrafish RB1 tumors resemble Human Olig2+/Sox10+ CNS-PNET subtype. 
A.) Heatmap of RPKM values from RB1-tumor transcriptome overlayed with a list of genes 
DE in Human Olig2+/Sox10+ CNS-PNET subtype from (Modzelewska et al. 2016) study, 
T= Tumor sample, C= Control sample. 
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B.)  
 
 
 
 
 
 
 
 
 
 
Figure 2.6 (Continued) B)  Heatmap of RPKM values from RB1-tumor transcriptome 
overlayed with a list of genes DE in 3 types of Human PNETs from (Picard et al. 2012) study 
rb1 – Tumor = Tumor samples 1-10, C = Control samples 1-2 . 
 
Cell proliferation in the RB/RB1-mutant and RB1- transformed cells are controlled by 
similar mechanisms. 
 
The transcriptomic analysis of zebrafish RB1- tumors indicated an oligoneural 
precursor phenotype drives tumor proliferation. To determine additional factors that cause 
Log2(RPKM) 
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transformation and oncogenesis when RB1 is absent, an RNA-Seq was performed on larval 
zebrafish homozygous for a recessive loss of function RB1 mutation (RB/7).  
Differential gene expression analysis of the RB/7 mutant revealed an upregulation 
of E2F targets driving cell cycle entry (Figure 2.7A). IPA showed differential gene 
expression in pathways controlling cell division, mitosis, and DNA replication, 
recombination and repair (Figure 2.7B), as expected for activation of E2F protein-dependent 
pathways in the absence of RB1. Taken together, these results suggest that the activation of 
molecular pathways driving cell proliferation in the RB/7 mutant and RB1- transformed 
cells are controlled by similar mechanisms.  
 
A.) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7 Cell proliferation in the RB1/ mutant and RB1- transformed cells are 
controlled by similar mechanisms. A.) Heatmap of RPKM expression values for E2F cell 
cycle target genes in Zebrafish RB1/7 transcriptome. 
Log2(RPKM) 
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B.)  
 
 
 
 
 
 
 
 
 
 
Figure 2.7 (Continued) B.) Ingenuity Pathway Analysis of differentially expressed genes in 
Zebrafish RB1/7 transcriptome.  
 
 
2.4: Discussion. 
 
The Retinoblastoma tumor suppressor gene is involved in many important 
developmental process’s with roles in cell fate, differentiation, self-renewal, and cell cycle 
control. Many types of cancer can arise from a deficiency in RB1. One such cancer in 
Primitive Neuroectodermal tumors of the central nervous system (CNS-PNET). This type of 
cancer is highly aggressive and can be devastating to those who have it. Therefore, there is a 
need to develop effective animal models of this cancer, so that research can be conducted 
into deducing the mechanisms that lead to tumorigenesis as well as identifying potential drug 
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targets. Our group has developed a zebrafish PNET model through somatic invitation of 
RB1. Upon genomic analysis, it is revealed that these tumors harbor a progenitor like 
signature, having genes such as Olig2 and Sox10 being overexpressed, while neurogenic 
factors are downregulated. This expression pattern overlaps with the Human Olig2+/Sox10+ 
CNS-PNET subtype. Comparative transcriptome analysis of zebrafish RB1-tumors and 
RB/7 mutant tissue also revealed that overexpression of oligoneural precursor 
transcription factors distinguish mutant from transformed. This indicates that the oligoneural 
precursor phenotype could be what drives tumor proliferation. 
Though there have been other zebrafish models of PNET, none have documented the 
role of epigenetics in this animal model, as has been done in Human and Mouse. This chapter 
showed that over 36% of all transcription regulators are differentially expressed, one fifth of 
those being chromatin remodelers ( >200 ). There is no doubt that epigenetics plays a vital 
role in our zebrafish PNET model. With the use of bioinformatics to identify candidate 
genes, this needs to be investigated further using molecular genetics.  
RBBP4, a chromatin adaptor for multiple chromatin remodeling complexes, is an E2F 
protein target and, as expected, was increased in the zebrafish rb1 tumor and rb1/ rb1 
homozygous mutant transcriptome. hdac1, which is not a direct target of E2F transcriptional 
activation, was highly upregulated in the tumor transcriptome, but only elevated 1.3-fold in 
the rb1/rb1 mutant. This suggests that hdac1 is one of many chromatin remodelers for which 
its activity might distinguish transformed tumor cells from mutant cells. Gene regulatory 
network analysis and simulation of tumorigenesis in a human cell line model has suggested 
that chromatin remodelers cooperate with transcription factors as cells progress to 
transformation (Malysheva et al. 2016). A similar epigenetic mechanism in which Hdac1 and 
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Rbbp4 associate with oligoneural precursor transcription factors might drive zebrafish rb1 
brain tumor oncogenesis. 
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CHAPTER 3: INVESTIGATION OF THE ZEBRAFISH CHROMATIN 
REMODELER, CHROMODOMAIN HELICASE DNA‐BINDING PROTEIN 7 WITH 
CRISPR/CAS9 TARGETED GENE EDITING. 
3.1: Introduction. 
 
Chromodomain helicase DNA‐binding protein 7 (CHD7) is a chromatin remodeler 
that plays a role in transcription regulation by remodeling chromatin, specifically unwinding 
the DNA around nucleosomes. Reports about the function of CHD7 suggest a role in 
regulating gene expression programs by ATP‐dependent chromatin remodeling in embryonic 
stem (ES) cells and other cell types (Bajpai et al. 2010, Schnetz et al. 2009). The CHD7 gene 
is highly conserved across species and orthologs have been identified in Xenopus, zebrafish, 
mouse, and chicken, among others (Aramaki et al. 2007, Bajpai et al. 2010, Bosman et al. 
2005). The zebrafish CHD7 amino acid (AA) sequence demonstrates 69% identity to the 
Human CHD7 AA sequence (Balow et al. 2013).  Additionally, the zebrafish and Human 
CHD7 protein contain similar domains including tandem N-terminal chromodomains, a 
central SNF2-like ATPase/helicase domain, and a C-terminal BRK domain (Balow et al. 
2013). There is also evidence for high functional importance of CHD7 as 
homozygous Chd7 mutant mice do not survive beyond an early embryonic stage, suggesting 
strong selective pressure for functional CHD7 protein (Hurd et al. 2007, Randall et al. 2009). 
Heterozygous mutations and deletions of CHD7 can result in CHARGE syndrome in 
Humans (MIM# 214800) (Janssen et al. 2012). CHARGE syndrome causes congenital 
anomalies including coloboma, heart defects, choanal atresia, retarded growth and 
development, genital hypoplasia, ear anomalies, and deafness (Jongmans et al. 2006). In 
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addition to this, a study found that 99% of patients with CHARGE exhibit a developmental 
delay and 74% have an intellectual disability (Bergman et al. 2011). In mice, deletion 
of CHD7 in a population of cerebellar granule cell progenitors (GCps) results in reduced 
GCp proliferation, cerebellar hypoplasia, developmental delay, and motor deficits (Whittaker 
et al. 2017).  
As a chromatin remodeler, CHD7 most likely has many binding sites and interacting 
partners. A study (Schnetz et al. 2010) used a genomics approach to explore CHD7 binding 
sites and interacting partners in embryonic stem (ES) cells via (ChIP-Seq). They found 
10,483 chromatin sites bound by CHD7, the majority of which appear to be enhancer 
regions. Interestingly, despite the many CHD7 binding sites in ES cell–specific genes, ES 
cell pluripotency, self-renewal, and reprogramming did not appear effected by CHD7 dosage. 
Thus, it would seem CHD7 acts as minor regulator of gene expression without overtly 
controlling ES cell function (Martin. 2010). In Humans and Xenopus, during 
embryogenesis, CHD7 and PBAF, a member of the SWI/SNF activating complex, 
cooperate to promote neural crest gene expression and cell migration (Bajpai et al. 2010). 
Sox2, a gene essential for maintaining self-renewal, or pluripotency, of undifferentiated 
embryonic stem cells (Fong et al. 2008) and has roles in neurogenesis (Pevny et al.  2010, 
as cited in Engelen et al. 2011), physically interacts with CHD7, and together they have 
overlapping genome-wide binding sites which control expression of Jag1, Gli3 and Mycn, 
genes mutated in Alagille, Pallister-Hall and Feingold syndromes, all of which show 
deformities also associated with SOX2 anophthalmia syndrome or CHARGE syndrome 
((Okuno et al. 1990, van Bokhove et al. 2005, Kang et al. 1997) as cited in Engelen et al. 
2011).  
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With these diverse developmental defects that result from a deficiency in CHD7 
protein, and its ability to regulate epigenetics, it raises the possibility that it may have a role 
in cancer. Indeed, CHD7 gene is known to be mutated in small cell lung cancer tissues 
(Sawada et al. 2013).  CHD7 is upregulated in the gene set of the 60 most highly upregulated 
and the 60 most downregulated genes in the human Olig2+/Sox10+ CNS-PNET subtype 
(Picard et al. 2012). It is also upregulated in our RB1-tumor PNET model mentioned in 
Chapter 2.  
As mentioned previously, mutations in CHD7 cause defects in brain development and 
CHARGE syndrome in humans, and loss brain tissue in mice. In addition to this CHD7 has 
been shown to promote proliferation of neural stem cells in mice (Ohta et al. 2016). It’s 
overexpression in cancer suggest it could be driving tumor cell proliferation or growth. With 
all these aspects of CHD7 in mind, CHD7 would seem like a good candidate to target in 
cancer studies. 
 
3.2: Methods 
 
CRISPR/Cas9 injection into Zebrafish Embryos: 
pT3TS-nCas9n was a gift from Wenbiao Chen (Addgene plasmid # 46757). XbaI linearized 
pT3TS-nCas9n was purified under RNase-free conditions with the Promega PureYield 
Plasmid Miniprep System. Linear, purified pT3TS-nCas9n was used as template for in vitro 
transcription of capped, polyadenylated mRNA with the Ambion T3TS mMessage 
mMachine Kit. mRNA was purified using Qiagen miRNeasy Kit. Short guide RNAs were 
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designed to exons 3 and 19 of CHD7 based off ensembl exon sequences Universal sgRNAs 
were generated using cloning free sgRNA synthesis as described in (Varshney et al. 2015) 
and purified using a Qiagen miRNeasy Kit. Wildtype Zebrafish embryos were injected with 
50pg of each gRNA and 150pg of Cas9 RNA. Embryos were incubated at 25 °C.  
Confirmation of mutagenesis 
 Each guide (CHD7 exon 3, 19) was confirmed to be mutagenic via heteroduplex 
formation assessed by agarose gel electrophoresis. This is done my doing a PCR that results 
in a small amplicon, ~150bp, which flanks the cutsite. If mutagenesis occurred, the band will 
appear smeary compared to widtype. This is due to the mosaic nature of somatic mutagenesis 
(Supplementary 3.1). 
 The deletion was also confirmed by doing a PCR with primers for exons 3 and 19 
(Supplementary 3.2). The only way a product could form in the amount of extension time 
given 15s, would be the deletion product (152bp), this is because without the deletion the 
product would be 15.6 kb, making the product impossible to obtain in that amount of 
extension time. GoTaq was used for PCR and its extension rate is 1000bp/60s. Deletion was 
further confirmed in founder by sequencing of PCR product (Supplementary 3.2).  Isolation 
of an F1 deletion mutant from injected founders was confirmed the same way the deletion 
was confirmed in the founders. 
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3.3: Results. 
 
Targeting CHD7 with endonucleases CRISPR/Cas9 to make deletion. 
Using the CRISPR/Cas9 endonuclease system, a 15.6 kb deletion was obtained by co-
injecting 50pg of gRNAs to exons 3 and 19 along with 150pg of Cas9 RNA into zebrafish 
embryos. This deletion would rid the CHD7 protein of its ATPase/helicase domain. Both 
guides are highly efficient at cutting (Supplementary 3.1). This was confirmed via PCR and 
sequencing (Supplementary 3.2). 
CHD7 protein coding transcript 203 
 
 
+     (50pg Exons 3,19 gRNA and 150pg Cas9 RNA) Injected into zebrafish embryo =  
 
 
       
 
Figure 3.1 Diagram of normal CHD7 gene and deletion gene.                                                                                     
Targeting of CRISPR endonuclease to exons 3 and 19 of the CHD7 gene in zebrafish 
embryos results in 15.6 kb deletion. 
 
1 // 55.03 kb (Normal gene) 2 
 
3 // 19 38 
1 39.43 kb (Deletion gene) 2 
 
3  19 // 38 
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Somatic targeting of CHD7 via CRISPR/Cas9 reveals larval phenotype  
 
When co-injecting gRNAs to exons 3 and 19 (50pg) of CHD7 with Cas9 RNA 
(150pg) into zebrafish embryos, the larva at 3dpf, display curvature of the body axis, 
microcephaly (Figure 3.2A), and severe pericardial edema compared to wild-type fish 
(Figure 3.2B). This is in agreement with the CHD7 morpholino knockdown phenotype in 
zebrafish (Patten et al. 2012). Approximately 30% of the fish showed a phenotype in the first 
injection and 25% in the second. This is suggestive of CHD7 being depleted reproducibly by 
the CRISPR system. 
A.)   
 
 
 
 
 
 
B.) 
 
 
 
 
 
Figure 3.2 Somatic targeting of CHD7 results in phenotype. Zebrafish larva 3dpf: 
Wildtype and CRISPR injected (50pg gRNA CHD7 exons 3 and 19, 150pg Cas9 RNA). A.) 
Wildtype compared to Injected. Injected show microcephaly and bent body axis. B.) Injected 
with severe pericardial edema.  
 
Wildtype Injected Injected 
Injected 
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Isolation of CHD7 germline deletion mutant  
 
Using the founders co-injected with CHD7 3-19 gRNAs, 2/20 F1s from a mating of 
founders and wildtype zebrafish carried the CHD73-19 deletion allele (Figure 3.3). 
Sequencing of these PCR amplicons (~150bp) confirmed the 15.6 kb deletion between exons 
3 and 19 of CHD7 (Figure 3.1). Interestingly, upon growing up these CHD7 +/- F1s, they 
appeared to be normal. Humans that are heterozygous for a CHD7 loss of function mutation 
can develop CHARGE syndrome. Similar symptoms to CHARGE syndrome can also be seen 
in mice in heterozygous mutants (Bosman et al. 2005). Both zebrafish isolated were female, 
so they were grown up and mated with wildtype to establish a line of F2s with the CHD7+/- 
allele which should allow for a matting between two CHD7+/- fish to see the homozygous 
mutant phenotype.  
 
Figure 3.3 Isolation of CHD7 15.6kb deletion in F1 zebrafish. Agarose gel of wildtype (C) 
and F1s from CRISPR (CHD7 3-19 gRNAs, Cas9 RNA) injected founder and wildtype 
matting (1-20). 
 
MM  C     1      2    3      4     5     6     7    8     9   10  11   12          13  14   15   16   17 
MM  18  19   20 
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3.4: Discussion. 
CHD7 is a gene involved in early embryonic development, as evident in homozygous 
loss of function mice being not viable. CHD7 has implications in cancer, being upregulated 
in lung cancer as well as the Human Olig2/Sox10 subtype of primitive neuroectodermal 
tumor. It is also overexpressed in our zebrafish PNET brain tumor model.  
When targeting CHD7 somatically in zebrafish embryos with the CRISPR/Cas9 
system, at 3dpf they display a larval phenotype. This phenotype consist of curvature of the 
body axis, microcephaly, and pericardial edema. These abnormalities are evidence of CDH7s 
important role in development. Furthermore, the same phenotypes result from morpholino 
knockdown studies. Interestingly, the isolated heterozygous 15.6kb deletion mutant (exons 3-
19) does not display any obvious phenotypes. This is in contrast to Mice and Human studies 
in which there is a phenotype in CHD7 heterozygotes. Mice display brain development 
abnormalities and Humans develop CHARGE syndrome. An explanation for this absence of 
a phenotype in the 15.6 kb zebrafish deletion mutant may be due to the dominant negative 
nature of the CHD7 seen in tadpoles (Bajpai et al. 2010). Perhaps the zebrafish 15.6 kb 
deletion rids the CHD7 protein of its dominant negative nature, making the wild type allele 
functional enough for normal development. If this is true, then creating a dominant negative 
form of the CHD7 protein in zebrafish via targeted mutagenesis could prove useful for 
creating zebrafish CHARGE syndrome models. 
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CHAPTER 4 
SOFTWARE DEVELOPMENT TO MAP SLEEPING BEAUTY TRANSPOSON 
INTEGRATION SITES IN THE ZEBRAFISH GENOME. 
4.1: Introduction. 
 
 
 The Sleeping Beauty DNA transposon system was first developed over 2 decades 
ago as method of genetic transformation and insertional mutagenesis in vertebrates (Ivics et 
al. 1997). It is an ancient Tc1-like autonomous DNA transposon from the Teleost Fish which 
was made active, allowing it to insert and excise itself on its own via the “cut and paste” 
method. This system has worked in fish as well as in mouse and human cells (Ivics et al. 
1997). 
Recently, there has been an improvement to Sleeping Beauty transposase, called SB11. With 
SB11 one can achieve a 100-fold above those transpositions achieved with plasmids that 
insert into chromosomes by random recombination (Geurts et al. 2003). 
The Sleeping Beauty transposon system has the ability to overcome the limitations 
associated with viral gene transfer vectors and transient non-viral gene delivery approaches. 
The Sleeping Beauty system allows for high-level stable gene transfer and 
sustained transgene expression in multiple primary human somatic cell types, making it 
attractive for clinical use (Kebriaei et al. 2017). 
In addition to gene delivery, the Sleeping Beauty transposon system is also capable of 
inducing mutagenesis for functional genomic studies (Dupuy et al. 2005). One such example 
is Sleeping Beauty’s ability to induce tumors by inactivating tumor suppressors (Brett et al. 
2011). With the seemingly randomness of the transposition as well as the complexity of the 
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genome, bioinformatics is needed to address the mapping of these transposon insertion sites. 
With the advent of next generation sequencings technology, the ability to generate vast 
amounts of data from the Sleeping Beauty system is possible. Using available software it is 
possible to establish an efficient pipeline for mapping these transposon insertion sites in 
genomes (Brett et al. 2011). Here I present an efficient pipeline for mapping the Sleeping 
Beauty transposon to the zebrafish. I also present a program that takes in mapping data and 
adds gene and feature information to each discovered insertion site (gene name, Exonic, 
Intronic, Intergenic) as well as some additional information such as nearest gene for 
intergenic regions and orientation relative to a gene. The ability of this pipeline to identify 
Sleeping Beauty transposon insertion sites is validated with molecular genetics. The use of 
this pipeline and software (FishingForSleepingBeauty) will be valuable to those who wish to 
perform functional genomic studies using not only the Sleeping Beauty Transposon but all 
transposon systems.  
 
4.2: Methods 
 
Filtering the raw data 
Since the Sleeping Beauty transposon only inserts itself in regions of the genome that 
contain the TA nucleotides, reads that contained the transposon arm with “TA” adjacent to 
them were selected for using “more file.fastq | grep –A1 –B2 
“TGTATGTAAACTTCCGACTTCAACTGTA”. Reads where then sorted by barcode using 
the Barcode_Splitter feature of FASTX (Supplementary 4.1). Each barcode was 6bp in length 
and there were a total of 24 barcodes. The transposon sequence was then trimmed off using 
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Trimmomatic, leaving only the genomic sequence for alignment. Lastly, the reads had to be 
converted from fastq to fasta format in order to be compatible with the Bowtie alignment 
(Supplementary 4.3). Supplementary code 4.3 was used with supplementary 4.2 code for 
simplicity.   
 
Alignment to zebrafish reference genome and quantification.  
Bowtie was used for the filtered read alignment, since it is not a spliced aligner. The 
parameters used were based off the (Brett et al. 2011) study “-best –f –k2 –p7 –v3”.  This 
gives the top two hits and only allows 3 mismatches in the read sequence (Supplementary 
4.3). The alignment output was in SAM format and was filtered using the following criteria: 
the best match had to be at least 90% identical, including a perfect match to the ‘‘TA’’ at the 
start of the alignment, be at least 5% better than the second best match, and have 2 or less 
mismatches (Supplementary 4.3). The reads were counted and sorted using various unix 
commands to determine insertion frequency and location in the genome. The result of these 
commands outputs a 4 column file (Read_Count | Insertion_Location  | 
Chromosome_Number  | strand aligned too) (Supplementary 4.3). Supplementary code 4.3 
was used with supplementary 4.2 code for simplicity.  
 
Annotation of alignment results. 
The FishingForSleepingBeauty takes in this 3 column file and adds in valuable 
information such as gene name, gene feature (Exon, Exon number, Intron) and detects 
Intergenic insertion sites. It also adds some additional information such as nearest gene for 
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intergenic insertions and orientation relative to a gene (Supplementary 4.4). This software 
must also use 2 files to add all the necessary information; ZebraFishGene.gff (Supplementary 
4.5) and GeneFeature.gff (Supplementary 4.6).  
 
Molecular genetic verification of insertion sites.  
When an insertion site of interest is detected, using the genomic location information, 
primers can be designed for detection of a true insertion. These primers simply flank the 
potential insertion site and a PCR followed by sequencing is done to confirm it.  
 
4.3: Results. 
  
Transposon mapping pipeline outputs precise insertion frequency and genomic location 
information. 
The pipeline established filterers, aligns, and counts the raw reads to output potential 
Sleeping Beauty transposon insertion sites in the zebrafish genome. The output from the 
pipeline is informative as it makes a predictive and testable scenario (Table 4.1). 
Table 4.1 Transposon insertion locational information.                                                    
The frequency of reads mapped to a predicted insertion location. The orientation of the read 
in the reference genome.   
 
 
Read Count Location Chromosome # Alignment 
Orientation 
 
186 37368708 1 - 
86 40387948 5 + 
85 22060064 20 + 
62 40461110 4 + 
48 37318502 18 - 
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FishingForSleepingBeauty program annotates insertion file to provide meaningful 
interpretation    
The FishingForSleepingBeauty program takes in the insertion file and using the 
Zebrafish GTF file, adds in gene name, geneID, and gene feature information. In addition to 
this, the program lets the user know the insertion orientation relative to the coding strand of a 
gene and the nearest gene if mapped to an Intergenic location. The file is output in a text file 
format (Table 4.2). 
Table 4.2 FishingForSleepingBeauty Output.                                              
FishingForSleepingBeauty program output in excel. File contains locational information as 
well as orientation and feature.  
 
 
 
 
 
Whole chromosome integration frequency plots 
Using a text file generated from the FishingForSleepingBeauty program, insertion 
frequency plots for each chromosome can be generated. This is done in Microsoft excel by 
FREQUENCY function, plotting the number of unique insertions per 1000kb bin. The 
highest frequency chromosome transposon insertion was in chromosome 3.  Other 
chromosomes averaged 1-2 per bin (Figure 4.1). 
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Figure 4.1 Sleeping Beauty transposon insertion frequency.                                                    
Frequency plots of Sleeping Beauty transposon insertion sites per 1000kb bin on individual 
chromosomes.  
 
Molecular conformation of Sleeping Beauty integration site. 
The computational analysis of the Sleeping Beauty transposons was confirmed via 
molecular genetics. Two genes that showed high insertion frequency, high read count, were 
selected for molecular conformation. Gene CKD9 had in read count of 4139 and gene 
CENPP had a read count of 45,000. PCR of cloned junction fragments show the predicted 
band size, 600bp for CDK9 and 435bp for CENPP (Figure 4.2A, B). Sequencing was 
performed on clones with predicted insertion bands and were proven to have the transposon 
arm sequence in them with the adjacent “TA” (Figure 4.2D, E).  
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A.)                                                                      B.)  
 
 
 
 
 
 
 
 
 
C.) 
CDK9  
TAAGACAGGGAATTTTTACTAGGATTAAATGTCAGGAATTGTGAAAAAGTGAGT
TTAAATGTATTTGGCTAAGGTGTATGTAAACTTCCGACTTCAACTGTAGATTAAG
TAACATCATTGTGxTCACCACGCTATATACATTTCCTTCGGAGTTTCATGTCATTT
CAAGCATTTCATTTATAAATTATCGACTTTTAACTGCAGTTTGGTGGTTTCACTTT
CATCTGGGAACATTTTATTCATGATAAATTTATCAAAAGAACATAGGAAATACTA
GTTTGTAACTTTAACCAACATAATGGAGAGTTTTGTACAGCTGAAAACAAAAGG
AAAAGAATGACCTACCCCTACAAAAAAAGCCACAATATTATTGTGTGCATGCCG
AAGCAGCTGTATCCAAGGGCGAATTCGTTTAAA 
D.) 
Cenpp 
CAATTGTTGGAAAAATGACTTGTGTCATGCACAAAGTAGATGTCCTAACTGACTT
GCCAAAACTATTGTTTGTTAACAAGAAATTTGTGGAGTAGTTGAAAAACGAGTTT
TAATGACTCCAACTTAAGTGTATGTAAACTTCCGACTTCAACTGTATATTTTAAT
GAGAGTATAATTGAAATAATTTCGTTCAGCCCGTCAAATTCTTTTAGGACACCAC
TAGTAAATCTTGGTAAATCAAGTTTTTTTTCTTTTCAAACTCTCATGATTCCACAT
TGTCACTCTGTCATCAAGGGCGAATTCGTTTAAACCTGCAGGACTAGTCCCTTTA
GTGAGGGTTAATTCTGAGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGA
TTGTTATCCGCTCACAA 
Figure 4.2 PCR and sequencing validation of transposon insertion sites. PCR amplicons 
for CDK9 (A) and CENPP (B). Sequencing of clones for CDK9 (C) and CENPP (D), 
transposon arm in yellow, “TA” adjacent to each arm. 
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4.4: Discussion. 
The Sleeping Beauty transposon system has the ability to induce tumors through 
random mutagenesis of tumor suppressors and can introduce genetic constructs in the 
research sector as well as in clinical trials. This system being seemingly random, may have 
“hot spots” for insertion in certain locations of the genome. Finding these hotspots would 
prove valuable for studies that want to induce mutagenesis though inactivation of certain 
genes, as the hotspots could be considered unwanted background mutagenesis. Therefore, to 
find these hotspots, the use of bioinformatics is almost certainly needed.  
In this chapter, I presented a pipeline that effectively finds insertion sites and predicts 
these hotspots. It presents a method for filtering the raw data from the sequencing platform, 
since sequencing errors and errors in library prepetition can produce inaccurate reads. These 
reads are eliminated by selecting for paramount features of the Sleeping Beauty transposon, 
such as the required “TA” adjacent to the transposon arm. The data is then mapped to the 
most up to date reference genome using the non-splicing aligner, bowtie2, since splice 
junctions should not be of interest. Once the Mapping data is in the correct format, it is ran 
through the program “FishingForSleepingBeauty”. The program adds useful annotation 
information to the mapping results, which makes the data easy to interpret and identify 
hotspots for insertion. This pipeline is validated with molecular genetics and has identified 
hotspots such as the one on Chromosome 3 (Figure 4.1). This pipeline would also be useful 
for mapping other types of transposons, since the mapping formatted file for 
FishingForSleepingBeauty is universal.    
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APPENDIX A: SUPPLEMENTARY INFORMATION FOR CHAPTER 3  
 
 
 
Supplementary 3.1 CHD7 gRNAs are mutagenic  
 
1.2% Agarose gel of PCR amplicons flanking CRISPR cut-sites. Wildtype Control(C) and 
CRISPR injected (I). CHD7 Exon 19 CRISPR (right), CHD7 Exon 3 CRISPR (left).  
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Supplementary 3.2 Conformation of CDH7 15.6kb deletion  
 
Confirmation of CHD7 exon 3-19 deletion. 1.2% Agarose gel of PCR amplicons for 
predicted 152bp deletion product. Wildtype (C) and CRISPR injected (I). 
 
 
Sequencing of deletion product I5: Exon 3 in yellow, Exon 19 in Blue.  
 
CATTCTCCACCAGACCCTTCCCTGGAGATTATAACATCTAGTAAGACACCTGCCA
TGGAGGAGGATGAGGGATCCAAGTTCTGTGAAGAAGACATTGATCAGATTTTGC
AGAGACGTACACAGACCATTACAATTGAATCAGAAGGCAAAGGCTCAACATTTG
CTAAG 
 
 
 
MM  C     I1     I2    I3     I4    I5     I6    I7     I8 
200 
 
100 
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APPENDIX B: SUPPLEMENTARY INFORMATION FOR CHAPTER 4  
  
 
Supplementary 4.1 FASTX barcode splitter.  
##This code takes in multiplexed fastq file and separated them based on their barcode.  
 
#!/bin/bash 
#PBS  -o BATCH_OUTPUT.Ht-Seq 
#PBS  -e BATCH_ERRORS.HT-Seq 
#PBS -lnodes=1:ppn=16:compute,walltime=12:00:00 
cd $PBS_O_WORKDIR 
 cat  
/work/LAS/jahaltom/T2OncMapping/MiSeq_AK6WA/Undetermined_S0_L001_R1_001.fas
tq | /shared/software/LAS/fastx_toolkit/0.0.14/bin/fastx_barcode_splitter.pl --bcfile 
Barcode.part.txt --prefix Barcode.part --bol  --mismatches 1 
 
Supplementary 4.2 Code used with supplementary code 4.3 
Chmod activated code that creates and submits PBS scripts based on two parameters, “ID” 
prefix of the output PBS script, and “FASTQFile” file you want to map. This must be used 
with “Zebra” Masterfile in Supplementary 4.3. To use this code, one must have the Zebra 
Masterfile in working directory, then type:       ./Map ID Fastqfile. Code is below.  
 
#Map ID FASTQFile 
cp  Zebra  Zebra.$2 
perl -i -pe 's/infile/'$1'/g'  Zebra.$2 
perl -i -pe 's/identifier/'$2'/g' Zebra.$2 
qsub Zebra.$2 
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Supplementary 4.3 “Zebra” Master file used with supplementary code 4.2 
 
#!/bin/bash 
 
#PBS  -o BATCH_OUTPUT.Ht-Seq 
#PBS  -e BATCH_ERRORS.HT-Seq 
 
#PBS -lnodes=1:ppn=16:compute,walltime=12:00:00 
 
cd $PBS_O_WORKDIR 
 
mv infile  infile.2 
 
module load LAS/trimmomatic/0.33 
 
module load LAS/java/1.8.0_60 
 
java -jar /shared/software/LAS/trimmomatic/0.33/bin/trimmomatic-0.33.jar SE -threads 3 -
phred33 -trimlog logfile infile.2 infile.trimmed.fastq HEADCROP:32 MINLEN:25 
 
rm infile.2 
 
##Fastq_to_Fasta 
 
 awk 'BEGIN{P=1}{if(P==1||P==2){gsub(/^[@]/,">");print}; if(P==4)P=0; P++}' 
infile.trimmed.fastq > infile.trimmed.fasta 
rm infile.trimmed.fastq 
 
module load LAS/bowtie/1.1.2 
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bowtie   --best -f -k2 -p7 -v3 
/work/LAS/jahaltom/ZebraFishDatabase/ZebraFish/Bowtie_DataBase/ZebraFishV10 
/work/LAS/jahaltom/T2OncMapping/infile.trimmed.fasta -S identifier 
 
 
echo>txt 
 
###TA-----Uniq 
 
##Makes sure no alignment is at position 0 and there are no mismatches in the first two bases 
of the read. The “TA” .  
more identifier | grep -v "@" | awk '{if($4 > 0){print $12,$13,$14,$10,$3,$4,$2,$1,$6}}' | 
awk '{print $1,$2,$4,$5,$6,$7,$8,$9}' | awk '{if($6 ==0){print}}' | grep -v "MD:Z:0" | grep -
v "MD:Z:1"  > TAUniqs-10-19 
##Gets back any MD:Z tags that have matches between 10-19. 
more identifier | grep -v "@" | awk '{if($4 > 0){print $12,$13,$14,$10,$3,$4,$2,$1,$6}}' | 
awk '{print $1,$2,$4,$5,$6,$7,$8,$9}' | awk '{if($6 ==0){print}}' | awk 
'{if(substr($2,6,7)>=10 && substr($2,6,7)<=19) print }'   > TAUniq10-19 
## Combines previous two files  
cat TAUniqs-10-19 TAUniq10-19 > TAUniqs 
## ensures that there is a “TA” at the start of every read. 
more TAUniqs |  awk '{if(substr($3,1,2)=="TA") print $7,$8,$2,$5,$4}' > TAGenomic 
## Grabs the names of all the uniq mapped reads.  
more TAGenomic |  awk '{print $1}' | sort | uniq -c | grep -v "2 " | awk '{print $2}' > 
TAUniqNames 
##  Grabs data from TAGenomic that relates to each uniq mapped read.  
more txt | awk 'FNR==NR {a[$1]; next} $1 in a' TAUniqNames TAGenomic | awk '{print 
$3,$2,$4,$5}' > TA-Uniqs 
## Outputs location, chromosome number, and strand orientation.  
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more TA-Uniqs | grep -v "Zv" | awk '{print $3,$4,"+"}' | sort  > TAUniq 
 
rm TAUniqs-10-19 
rm TAUniq10-19 
rm TAUniqs 
rm TAGenomic 
rm TAUniqNames 
rm TA-Uniqs 
 
 
 
 
####-----TA Uniq 
##Makes sure no alignment is at position 0 and there are no mismatches in the last two bases 
of the read. The “TA” .  
 
more identifier | grep -v "@" | awk '{if($4 > 0){print $12,$13,$14,$10,$3,$4,$2,$1,$6}}' | 
awk '{print $1,$2,$4,$5,$6,$7,$8,$9}' | awk '{if($6 ==16){print}}' | awk 
'{if(substr($2,length($2),length($2))> 1 )print}' > UniqTA2-9 
more identifier | grep -v "@" | awk '{if($4 > 0){print $12,$13,$14,$10,$3,$4,$2,$1,$6}}' | 
awk '{print $1,$2,$4,$5,$6,$7,$8,$9}' | awk '{if($6 ==16){print}}' | awk 
'{if(substr($2,length($2)-1,length($2))==10 || substr($2,length($2)-1,length($2))==11 || 
substr($2,length($2)-1,length($2))==20 || substr($2,length($2)-1,length($2))==21 || 
substr($2,length($2)-1,length($2))==30 || substr($2,length($2)-1,length($2))==31 || 
substr($2,length($2)-1,length($2))==40 || substr($2,length($2)-1,length($2))==41 || 
substr($2,length($2)-1,length($2))==50 || substr($2,length($2)-1,length($2))==51 )print}' > 
UniqTAGre10 
## Combines the previous two files.  
cat UniqTA2-9 UniqTAGre10 > UniqsTA  
## ensures that there is a “TA” at the end of every read. 
more UniqsTA | awk '{if(substr($3,length($3)-1,length($3))=="TA" ) print $7,$8,$2,$5,$4}' 
> GenomicTA 
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## Grabs the names of all the uniq mapped reads.  
more GenomicTA |  awk '{print $1}' | sort | uniq -c | grep -v "2 " | awk '{print $2}' > 
UniqNames 
##  Grabs data from GenomicTA that relates to each uniq mapped read.  
more txt | awk 'FNR==NR {a[$1]; next} $1 in a' UniqNames GenomicTA | awk '{print 
$3,$2,$4,$5}' > Uniqs 
## Outputs location, chromosome number, and strand orientation.  
more Uniqs | sed -e 's/M / /g' | grep -v "Zv" | awk '{print $3+$2-1,$4,"-"}' | sort  > UniqTA 
 
 
rm UniqTA2-9 
rm UniqTAGre10 
rm UniqsTA 
rm GenomicTA 
rm UniqNames 
rm Uniqs 
 
 
 
 
 
##-----TA Mult 
##All Mismatch tags ending in 1 or 0 are removed. 
more identifier | grep -v "@" | awk '{if($4 > 0){print $12,$13,$14,$10,$3,$4,$2,$1,$6}}' | 
awk '{print $1,$2,$4,$5,$6,$7,$8,$9}' | awk '{if($6 ==16){print}}' | awk 
'{if(substr($2,length($2),length($2))> 1 )print}' > MultTA2-9 
##The mismatch tags (10,11,20,21,30,31,40,41,50,51) that would have been removed in the 
previous command are extracted. 
more identifier | grep -v "@" | awk '{if($4 > 0){print $12,$13,$14,$10,$3,$4,$2,$1,$6}}' | 
awk '{print $1,$2,$4,$5,$6,$7,$8,$9}' | awk '{if($6 ==16){print}}' | awk 
'{if(substr($2,length($2)-1,length($2))==10 || substr($2,length($2)-1,length($2))==11 || 
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substr($2,length($2)-1,length($2))==20 || substr($2,length($2)-1,length($2))==21 || 
substr($2,length($2)-1,length($2))==30 || substr($2,length($2)-1,length($2))==31 || 
substr($2,length($2)-1,length($2))==40 || substr($2,length($2)-1,length($2))==41 || 
substr($2,length($2)-1,length($2))==50 || substr($2,length($2)-1,length($2))==51 )print}' > 
MultTAGre10 
##The files are now combined. This file should not contain  T0,G0,C0,A1,C1,G1. No 
mismatches in the 93TA94. All reads will also contain the TA at the end of the read. . 
cat MultTA2-9 MultTAGre10 > MultTA 
more MultTA | awk '{if(substr($3,length($3)-1,length($3))=="TA" ) print $7,$8,$2,$5,$4}' > 
GenomicTA 
 
##Extracts all the Illumina Names that contain a Mult alignment. 
more GenomicTA |  awk '{print $1}' | sort | uniq -c | grep -v "1 " | awk '{print $2}' > 
MultNames 
##Extracts data from GenomicTA that is a mult aligned read.  
more txt | awk 'FNR==NR {a[$1]; next} $1 in a' MultNames GenomicTA | sort | awk '{print 
$1,$3,$2,$4,$5}' > Mults 
##Counts mismatches 
more Mults | awk '{print $2}' | sed 's/[^G,A,C,T]//g' | awk '{ print length }' > Counts 
##This rearranges the file. 
more txt | awk 'NR==FNR{a[NR]=$0;next}{print a[FNR],$0}' Counts Mults | awk '{a=$1; 
b=$2; c=$3; x=$4; l=$5; k=$6; getline; d=$1; e=$2; f=$3; y=$4 ; m=$5; n=$6; {print 
a,b,c,x,l,k,d,e,y,f,m,n}}' | sed -e 's/M / /g' | awk '{if((($4-$1)/$4 - ($9-$7)/$9) >= 0.05 || (($4-
$1)/$4 - ($9-$7)/$9) <= -0.05) print}' | awk '{if($1<$7) print $1,$5,$6,$4; else print 
$7,$11,$12,$9; }' | awk '{if(($1 <=2) && (($4-$1)/$4 >=0.90))print $2+$4-1,$3,"-"}' | grep -
v "Zv" | sort   >  Mult_TA 
 
rm MultTA2-9 
rm MultTAGre10 
rm MultTA 
rm GenomicTA 
rm  MultNames 
rm Mults 
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rm Counts 
 
##TA---- Mult 
more identifier | grep -v "@" | awk '{if($4 > 0){print $12,$13,$14,$10,$3,$4,$2,$1,$6}}' | 
awk '{print $1,$2,$4,$5,$6,$7,$8,$9}' | awk '{if($6 ==0){print}}' | grep -v "MD:Z:0" | grep -
v "MD:Z:1"  > TAMult-10-19 
more identifier | grep -v "@" | awk '{if($4 > 0){print $12,$13,$14,$10,$3,$4,$2,$1,$6}}' | 
awk '{print $1,$2,$4,$5,$6,$7,$8,$9}' | awk '{if($6 ==0){print}}' | awk 
'{if(substr($2,6,7)>=10 && substr($2,6,7)<=19) print }'   > TAMult10-19 
##The files are now combined. This file should not contain or T0,G0,C0,A1,C1,G1. No 
mismatches in the 93TA94. All reads will also contain the ---TA orientation. 
cat TAMult-10-19 TAMult10-19 > TAMults 
more TAMults |  awk '{if(substr($3,1,2)=="TA") print $7,$8,$2,$5,$4}' > TAGenomic 
more TAGenomic |  awk '{print $1}' | sort | uniq -c | grep -v "1 " | awk '{print $2}' > 
MultNames 
##A Mults File must be made to add counts too using the previous two files. 
more txt | awk 'FNR==NR {a[$1]; next} $1 in a' MultNames TAGenomic | sort | awk '{print 
$1,$3,$2,$4,$5}' > Mults 
##Counts mismatches 
more Mults | awk '{print $2}' | sed 's/[^G,A,C,T]//g' | awk '{ print length }' > Counts 
##This rearranges the file. 
more txt | awk 'NR==FNR{a[NR]=$0;next}{print a[FNR],$0}' Counts Mults | awk '{a=$1; 
b=$2; c=$3; x=$4; l=$5; k=$6; getline; d=$1; e=$2; f=$3; y=$4; m=$5; n=$6; {print 
a,b,c,x,l,k,d,e,y,f,m,n}}' | sed -e 's/M / /g' | awk '{if((($4-$1)/$4 - ($9-$7)/$9) >= 0.05 || (($4-
$1)/$4 - ($9-$7)/$9) <= -0.05) print}' | awk '{if($1<$7) print $1,$5,$6,$4; else print 
$7,$11,$12,$9; }' | awk '{if(($1 <=2) && (($4-$1)/$4 >=0.90))print $2,$3,"+"}' | grep -v 
"Zv" | sort >  TA_Mult 
 
 
rm Counts 
rm Mults 
rm MultNames 
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rm TAGenomic 
rm TAMults 
rm TAMult10-19 
rm TAMult-10-19 
 
cat TAUniq UniqTA Mult_TA TA_Mult | sort | uniq -c | sort -rn  | grep -v " -1" | grep -v "3   
+"   > identifier.txt 
 
rm txt 
rm TAUniq 
rm UniqTA 
rm TA_Mult 
rm Mult_TA 
 
 
 
 
Supplementary 4.4 FishingForSleepingBeauty Java Script 
 
package ReadCounter; 
import java.io.File; 
import java.io.FileNotFoundException; 
import java.io.PrintWriter; 
import java.util.Scanner; 
public class ReadCount { 
 
public static void main(String[] args) throws FileNotFoundException{ 
 
 ReadCount c = new ReadCount(); 
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 File f = new File("/Users/Jeff/Desktop/ZebraFish"); 
 
 File[] list = f.listFiles(); 
 for (File i: list){ 
  File File1 = new File("/ZebraFish/src/ReadCounter/ZebraFishGene.gff"); 
  File File2 = i; 
 
  c.Count(File1, File2, i.getName());}} 
public void Count(File file1, File file2, String name) throws FileNotFoundException{ 
  
File outfile = new File(name); 
PrintWriter out = new PrintWriter(outfile); 
String gene_ID=""; 
String chr=""; 
int start=0; 
int end=0; 
String Name=""; 
String Chr2=""; 
int start2=0; 
int end2=0; 
String Name2=""; 
String gene_ID2=""; 
int count = 1; 
Scanner scan = new Scanner(file1); 
while (scan.hasNext()){ 
  
if (count == 1){  
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 Name=scan.next(); 
 gene_ID=scan.next(); 
 chr=scan.next(); 
 start=scan.nextInt(); 
 end=scan.nextInt();} 
 Name2=scan.next(); 
 gene_ID2=scan.next(); 
 Chr2=scan.next(); 
 start2=scan.nextInt(); 
 end2=scan.nextInt(); 
 
 Scanner scan2 = new Scanner(file2); 
 while (scan2.hasNext()){ 
  int read=scan2.nextInt(); 
  int insert=scan2.nextInt(); 
  String chr2=scan2.next(); 
  String ori = scan2.next(); 
 
   if (chr2.equals(chr) && insert >= start && insert <= end){ 
    out.println(1 + " " + name + " " + gene_ID + " " + Name + " " 
+ chr2 + " " + insert + " " + read + " " + ori ); } 
   if (chr2.equals(Chr2)  && insert >= start2 && insert <= end2){ 
    out.println(1 + " " + name + " " + gene_ID2 + " " + Name2 + " 
" + chr2 + " " + insert + " " + read + " " + ori );} 
 
   if( !(start2 <=end) && insert > end && insert < start2 && 
chr2.equals(Chr2) && chr2.equals(chr)){ 
    int x = start2 - insert; 
    int y = insert - end; 
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    if(x<=y){ 
    out.println(2 + " " + name + " " + gene_ID2 + " " + x + 
"_bp_from_" + Name2 + " " + chr2 + " "  + insert + " " + read);} 
    else if(y<x){ 
    out.println(2 + " " + name + " " + gene_ID + " " + y + 
"_bp_from_" + Name + " " + chr2 + " "  + insert + " " + read);} }} 
 count++; 
 Name=Name2; 
 gene_ID=gene_ID2; 
 chr=Chr2; 
 start=start2; 
 end=end2;} 
out.close(); 
 
File FILe = outfile; 
Scanner scan3 = new Scanner(FILe); 
File outfile2 = new File(name + "_.txt"); 
PrintWriter OUT = new PrintWriter(outfile2); 
 
while (scan3.hasNext()){ 
 int z = scan3.nextInt(); 
 if (z==1){  
     int Tell = 0; 
  String qq = scan3.next(); 
  String ID = scan3.next(); 
  String mm = scan3.next(); 
  int CHR = scan3.nextInt(); 
  int INSERT = scan3.nextInt(); 
  int READ = scan3.nextInt(); 
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  String ORI = scan3.next(); 
    
  File FILE = new File("/ZebraFish/src/ReadCounter/GeneFeature.gff"); 
  Scanner scan4 = new Scanner(FILE); 
  String PLUS_MINUS = " "; 
  while (scan4.hasNext()){ 
   String feature = scan4.next(); 
   int Start = scan4.nextInt(); 
   int End = scan4.nextInt(); 
   String GeneID = scan4.next(); 
   String ExonNum = scan4.next(); 
   String Bull = scan4.next(); 
 
   if (feature.equals("UTR")){ 
    ExonNum = "";} 
   if (ID.equals(GeneID) && ORI.equals(Bull)){ 
    PLUS_MINUS = " SAME";} 
   else if(ID.equals(GeneID) && (ORI.equals(Bull))==false){  
    PLUS_MINUS = " OPPOSITE";}  
   if (ID.equals(GeneID) && INSERT >= Start && INSERT <= End){ 
    OUT.println(" " + name + " " + ID + " " + mm + " " + CHR + " 
" + INSERT + " " + READ +  
      " " + feature + "_"+ ExonNum + " " + 
PLUS_MINUS ); OUT.flush(); 
    Tell =1; } 
   else{}  } 
  if (Tell == 0) {OUT.println(" " + name + " " + ID + " " + mm + " " + CHR + " 
" + INSERT + " " + READ +  
    " Intron " + PLUS_MINUS); OUT.flush();} } 
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 else { OUT.println(scan3.nextLine() + " Intergenic");  OUT.flush(); }} 
OUT.close(); 
scan3.close(); }} 
 
 
 
Supplementary 4.5 Zebrafish gene information file   
This is a row from a 5 column file that contains gene information for every gene in the 
zebrafish genome (Gene Name, Gene_ID, Chromosome number, start site, end site). This file 
was made from the zebrafish_V9.gff file.  
 
ZebraFishGene.gff: 
 
si:ch73-252i11.3  ENSDARG00000104632  4 6733 52120 
 
 
Supplementary 4.6 Zebrafish gene feature information file   
This is a 6 column file that contains gene feature information for every gene in the zebrafish 
genome (Feature (Exon, CDS, UTR), start site, end site, gene_ID, feature number (if coding 
exon), strand gene is on (+ or -)). This file was made from the zebrafish_V9.gff file.  
 
 
GeneFeature.gff 
 
exon 30383 30614 ENSDARG00000098417 1 + 
exon 33830 34259 ENSDARG00000098417 2 + 
CDS 16269 16549 ENSDARG00000100660 1 + 
UTR 33433 36772 ENSDARG00000098417 “ - 
